Definium Therapeutics Inc (DFTX) Proxy filing summary

Executive summary

• Annual General and Special Meeting scheduled for June 11, 2026, to be held virtually.

• Shareholders are encouraged to review proxy materials and vote by June 10, 2026.

Voting matters and shareholder proposals

• Election of seven directors to serve until the 2027 annual general meeting.

• Appointment of KPMG LLP as independent registered public accounting firm until the 2027 meeting.

• Proposal to amend the 2025 Equity Incentive Plan to increase available shares by 5,000,000.

• Board recommends voting in favor of all proposals.

Board of directors and corporate governance

• Director nominees include Robert Barrow, Suzanne Bruhn, Roger Crystal, David Gryska, Andreas Krebs, Carol A. Vallone, and Roger Adsett.